An antibody program can clear binding and look strong for two years.
Then expression, stability, or immunogenicity don’t pull through, and the whole thing falls apart.
Months of lab work, budget, and time — all gone. Leaving patients waiting.
It’s a familiar story. Why? Because many programs fix binding first and test other properties later.
But that makes trade-offs hard to see; you cannot score each property on its own and still find the design that satisfies all of them.
By year two this becomes an expensive problem to fix.
